Nodular Prurigo Global Market Report 2025

The nodular prurigo market size has grown strongly in recent years. It will grow from $1.17 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. Growth in the historical period was supported by an increase in dermatological consultations, greater awareness among skin specialists, unmet treatment needs, academic interest in the condition, and advancements in diagnostic capabilities.

The nodular prurigo market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. Contributing factors to this projected growth include the introduction of targeted therapies, enhanced R&D investment for rare skin conditions, more robust patient education and advocacy initiatives, broader insurance and reimbursement availability, and the development of companion diagnostics and biomarkers. Noteworthy trends anticipated during the forecast period include AI-assisted diagnostic tools, gene editing advancements, nanotechnology applications in treatment delivery, innovative biologic therapies, and the adoption of wearable monitoring technologies.

The rising demand for targeted therapies is anticipated to drive the growth of the nodular prurigo market. Targeted therapies are medical treatments designed to specifically interact with molecular pathways involved in disease progression. Their growing popularity stems from their precision, reduced side effects, and enhanced patient outcomes, making them favorable alternatives to traditional, broad-spectrum treatments. In the case of nodular prurigo, which presents a clear unmet need involving immune pathways such as IL-4, IL-13, and IL-31, targeted biologics can effectively block these inflammatory signals, leading to more successful treatment. For example, in October 2023, NHS England reported that 11 million hormone replacement therapy (HRT) items were prescribed in England - a 47% increase from 2021-22 - with approximately 2.3 million patients receiving prescriptions, reflecting a 29% year-on-year growth. This illustrates the broader trend of increased demand for targeted therapies, which is contributing to the expansion of the nodular prurigo market.

Major players in the nodular prurigo market are emphasizing regulatory approvals to broaden their market presence and enhance treatment outcomes. Regulatory approvals involve official authorization from government or regulatory agencies, allowing the public use and marketing of specific drugs or therapies. For example, in September 2022, Regeneron Pharmaceuticals Inc., a biotechnology firm based in the U.S., obtained FDA approval for Dupixent (dupilumab), making it the first and only treatment explicitly approved for prurigo nodularis in adults. This approval followed successful Phase 3 trials - PRIME and PRIME2 - which showed Dupixent significantly reduced itch and skin lesions compared to placebo. As a result, Dupixent emerged as the only medication in the U.S. with an approved indication for treating prurigo nodularis, addressing the needs of approximately 75,000 affected adults.

In April 2024, Incyte Corporation, a U.S.-based pharmaceutical company, formed a partnership with China Medical System Holdings Limited to advance the development and commercialization of Povorcitinib across Asia. The collaboration aims to support the treatment of various autoimmune and inflammatory dermatologic conditions, including non-segmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma, and chronic spontaneous urticaria. China Medical System Holdings Limited, based in Hong Kong, is actively involved in treatments related to nodular prurigo.

Major players in the nodular prurigo market are Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Galderma S.A., Galderma Laboratories L.P., Incyte Corporation, Kyowa Kirin Co Ltd., LEO Pharma A/S, Maruho Co Ltd., Kiniksa Pharmaceuticals Ltd., Keymed Biosciences Co Ltd., Trevi Therapeutics Inc., Fierce Pharma, Menlo Therapeutics Inc., VYNE Therapeutics Inc., and Celldex Therapeutics Inc.

North America was the largest region in the nodular prurigo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nodular prurigo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nodular prurigo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nodular prurigo, also referred to as prurigo nodularis, is a chronic dermatological condition characterized by extremely itchy, firm nodules that typically develop on areas such as the arms, legs, and torso. It is a persistent disorder of unknown origin involving immune, neurological, and inflammatory mechanisms, where continuous itching prompts repetitive scratching, leading to lesion aggravation, scarring, and often requiring long-term medical management by dermatologists.

The primary classifications of nodular prurigo include chronic nodular prurigo, acute nodular prurigo, and subacute nodular prurigo. Chronic nodular prurigo is a prolonged variant marked by the appearance of highly itchy, firm skin bumps. Treatments for the condition vary and may involve topical applications, systemic medications, phototherapy, and immunosuppressive agents. This condition affects various demographic groups, including adults, children, and the elderly, and treatment services are provided across different settings such as hospitals, homecare, specialty clinics, and others.

The nodular prurigo market research report is one of a series of new reports that provides nodular prurigo market statistics, including nodular prurigo industry global market size, regional shares, competitors with a nodular prurigo market share, nodular prurigo market segments, market trends and opportunities, and any further data you may need to thrive in the nodular prurigo industry. This nodular prurigo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nodular prurigo market consists of revenues earned by entities by providing services such as diagnosis and clinical evaluation, prescription of topical treatments, phototherapy, biologic therapies, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The nodular prurigo market also includes sales of products including oral antidepressants, JAK inhibitors, and topical calcineurin inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.